Product Information
OXCARBAZEPINE 150 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $0.1062 per EA under NDC 72888046201. Its NADAC has been published 41 times since Dec 24, 2025.
FDA first approved this application on Mar 5, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888046201
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXCARBAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA207717FDA Approved
3/5/2024
TE Code
AB
On Market Since
5/20/2025
Pharmacological Classes
Price Statistics
The NADAC for OXCARBAZEPINE 150 MG TABLET has been published 41 times since Dec 24, 2025, and over the history we have for it it has declined 7.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1062 per EA |
|---|---|
| All-time high | $0.1153 (Jan 14, 2026) |
| All-time low | $0.1036 (Jun 17, 2026) |
| 52-week high | $0.1153 |
| 52-week low | $0.1036 |
| Median price | $0.1059 |
| Average price | $0.1069 |
| Largest weekly change | -3.4% (Jun 17, 2026) |
| Weeks tracked | 41 |
| Tracking since | Dec 24, 2025 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxcarbazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXCARBAZEPINE 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXCARBAZEPINE 150 MG TABLET, manufactured by Advagen Pharma Ltd., is $0.1062 per EA (NDC 72888046201), effective Sep 30, 2026.
How has the price of OXCARBAZEPINE 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXCARBAZEPINE 150 MG TABLET has declined 7.8%. It has been tracked across 41 weekly CMS publications since Dec 24, 2025.
What are the highest and lowest recorded NADAC prices for OXCARBAZEPINE 150 MG TABLET?
Since Dec 24, 2025, the NADAC for OXCARBAZEPINE 150 MG TABLET has ranged from a low of $0.1036 (Jun 17, 2026) to a high of $0.1153 (Jan 14, 2026), with a median of $0.1059 per EA.
Are there cheaper alternatives to OXCARBAZEPINE 150 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXCARBAZEPINE 150 MG TABLET, is $0.1037 per EA — about 2% below OXCARBAZEPINE 150 MG TABLET.
Who manufactures OXCARBAZEPINE 150 MG TABLET?
OXCARBAZEPINE 150 MG TABLET (NDC 72888046201) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.